{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:53:40Z","timestamp":1792079620838,"version":"4.4.0"},"reference-count":56,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,3,12]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Angiosarcoma is a histologically and molecularly heterogeneous vascular neoplasm with aggressive clinical behavior. Emerging data suggests that immune checkpoint blockade (ICB) is efficacious against some angiosarcomas, particularly cutaneous angiosarcoma of the head and neck (CHN).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with histologically confirmed angiosarcoma treated with ICB-based therapy at a comprehensive cancer center were retrospectively identified. Clinical characteristics and the results of targeted exome sequencing, transcriptome sequencing, and immunohistochemistry analyses were examined for correlation with clinical benefit. Durable clinical benefit was defined as a progression-free survival (PFS) of \u226516 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>For the 35 patients included in the analyses, median PFS and median overall survival (OS) from the time of first ICB-based treatment were 11.9 (95% CI 7.4 to 31.9) and 42.5 (95% CI 19.6 to 114.2) weeks, respectively. Thirteen patients (37%) had PFS \u226516 weeks. Clinical factors associated with longer PFS and longer OS in multivariate analyses were ICB plus other therapy regimens, CHN disease, and white race. Three of 10 patients with CHN angiosarcoma evaluable for tumor mutational burden (TMB) had a TMB \u226510. Five of six patients with CHN angiosarcoma evaluable for mutational signature analysis had a dominant mutational signature associated with ultraviolet (UV) light. No individual gene or genomic pathway was significantly associated with PFS or OS; neither were TMB or UV signature status. Analyses of whole transcriptomes from nine patient tumor samples found upregulation of angiogenesis, inflammatory response, and KRAS signaling pathways, among others, in patients with PFS \u226516 weeks, as well as higher levels of cytotoxic T cells, dendritic cells, and natural killer cells. Patients with PFS &lt;16 weeks had higher numbers of cancer-associated fibroblasts. Immunohistochemistry findings for 12 patients with baseline samples available suggest that neither PD-L1 expression nor presence of tumor-infiltrating lymphocytes at baseline appears necessary for a response to ICB-based therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ICB-based therapy benefits only a subset of angiosarcoma patients. Patients with CHN angiosarcoma are more likely to have PFS \u226516 weeks, a dominant UV mutational signature, and higher TMB than angiosarcomas arising from other primary sites. However, clinical benefit was seen in other angiosarcomas also and was not restricted to tumors with a high TMB, a dominant UV signature, PD-L1 expression, or presence of tumor infiltrating lymphocytes at baseline.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-004149","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T12:15:26Z","timestamp":1648815326000},"page":"e004149","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":52,"title":["Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7499-1279","authenticated-orcid":false,"given":"Evan","family":"Rosenbaum","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina R","family":"Antonescu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaleigh","family":"Smith","sequence":"additional","affiliation":[{"name":"Marie-Jos\u00e9e and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bradic","sequence":"additional","affiliation":[{"name":"Marie-Jos\u00e9e and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kashani","sequence":"additional","affiliation":[{"name":"Department of Medicine, SUNY Downstate Medical Center, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L","family":"Richards","sequence":"additional","affiliation":[{"name":"Marie-Jos\u00e9e and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Donoghue","sequence":"additional","affiliation":[{"name":"Marie-Jos\u00e9e and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara M","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Nacev","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"},{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Dickson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L","family":"Keohan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M","family":"Gounder","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujana","family":"Movva","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswatej","family":"Avutu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Thornton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Zehir","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8651-5317","authenticated-orcid":false,"given":"Anita S","family":"Bowman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Singer","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tap","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3736-3783","authenticated-orcid":false,"given":"Sandra","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"2025100312022602000_10.4.e004149.1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm381"},{"key":"2025100312022602000_10.4.e004149.2","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200505000-00011"},{"key":"2025100312022602000_10.4.e004149.3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(194805)1:1<64::AID-CNCR2820010105>3.0.CO;2-W"},{"key":"2025100312022602000_10.4.e004149.4","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(74)90683-7","article-title":"Angiosarcoma of the liver in a vinyl-chloride worker","volume":"303","author":"Lee","year":"1974","journal-title":"The Lancet"},{"key":"2025100312022602000_10.4.e004149.5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2068"},{"key":"2025100312022602000_10.4.e004149.6","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2921"},{"key":"2025100312022602000_10.4.e004149.7","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.090637"},{"key":"2025100312022602000_10.4.e004149.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.004"},{"key":"2025100312022602000_10.4.e004149.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.3146"},{"key":"2025100312022602000_10.4.e004149.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1"},{"key":"2025100312022602000_10.4.e004149.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30006-8"},{"key":"2025100312022602000_10.4.e004149.12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28581"},{"key":"2025100312022602000_10.4.e004149.13","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1253657","article-title":"Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma","volume":"6","author":"Honda","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100312022602000_10.4.e004149.14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JGO.2016.005843","article-title":"Positive PD-L1 expression predicts worse outcome in cutaneous angiosarcoma","volume":"3","author":"Shimizu","year":"2017","journal-title":"JGO"},{"key":"2025100312022602000_10.4.e004149.15","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.7150\/jca.19060","article-title":"Programmed death ligand 1 (PD-L1) expression in primary angiosarcoma","volume":"8","author":"Botti","year":"2017","journal-title":"J Cancer"},{"key":"2025100312022602000_10.4.e004149.16","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0689-7"},{"key":"2025100312022602000_10.4.e004149.17","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/cas.13981","article-title":"Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda\/iota in cutaneous angiosarcoma","volume":"110","author":"Kawamura","year":"2019","journal-title":"Cancer Sci"},{"key":"2025100312022602000_10.4.e004149.18","doi-asserted-by":"crossref","unstructured":"Hamacher R , K\u00e4mpfe D , Reuter-Jessen K , et al . Dramatic response of a PD-L1\u2013Positive advanced angiosarcoma of the scalp to pembrolizumab. JCO Precis Oncol 2018:1\u20137.doi:10.1200\/PO.17.00107","DOI":"10.1200\/PO.17.00107"},{"key":"2025100312022602000_10.4.e004149.19","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0263-0"},{"key":"2025100312022602000_10.4.e004149.20","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a004408"},{"key":"2025100312022602000_10.4.e004149.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0749-z"},{"key":"2025100312022602000_10.4.e004149.22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100312022602000_10.4.e004149.23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139080"},{"key":"2025100312022602000_10.4.e004149.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2014.12.006"},{"key":"2025100312022602000_10.4.e004149.25","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4333"},{"key":"2025100312022602000_10.4.e004149.26","unstructured":"Chakravarty D , Gao J , Phillips SM . OncoKB: a precision oncology knowledge base. JCO Precis Oncol 2017;2017:PO.1700011."},{"key":"2025100312022602000_10.4.e004149.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1943-3"},{"key":"2025100312022602000_10.4.e004149.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.035"},{"key":"2025100312022602000_10.4.e004149.29","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41568-020-0288-4","article-title":"The epigenomics of sarcoma","volume":"20","author":"Nacev","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2025100312022602000_10.4.e004149.30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-019-1038-1","article-title":"The expanding landscape of \u2018oncohistone\u2019 mutations in human cancers","volume":"567","author":"Nacev","year":"2019","journal-title":"Nature"},{"key":"2025100312022602000_10.4.e004149.31","doi-asserted-by":"crossref","unstructured":"Rosenbaum E , Jonsson P , Seier K , et al . Clinical outcome of leiomyosarcomas with somatic alteration in homologous recombination pathway genes. JCO Precis Oncol 2020:1350\u201360.doi:10.1200\/PO.20.00122","DOI":"10.1200\/PO.20.00122"},{"key":"2025100312022602000_10.4.e004149.32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective response rate among patients with locally advanced or metastatic sarcoma treated with Talimogene Laherparepvec in combination with pembrolizumab","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100312022602000_10.4.e004149.33","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"2025100312022602000_10.4.e004149.34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz1138"},{"key":"2025100312022602000_10.4.e004149.35","unstructured":"Broad Institute . Picard toolkit, 2019. Available: https:\/\/broadinstitute.github.io\/picard\/"},{"key":"2025100312022602000_10.4.e004149.36","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3519"},{"key":"2025100312022602000_10.4.e004149.37","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4324"},{"key":"2025100312022602000_10.4.e004149.38","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v025.i14"},{"key":"2025100312022602000_10.4.e004149.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160791","article-title":"Natural cubic Spline regression modeling followed by dynamic network reconstruction for the identification of radiation-sensitivity gene association networks from time-course transcriptome data","volume":"11","author":"Michna","year":"2016","journal-title":"PLoS One"},{"key":"2025100312022602000_10.4.e004149.40","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20827"},{"key":"2025100312022602000_10.4.e004149.41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/annonc\/mdw444","article-title":"A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas","volume":"28","author":"Agulnik","year":"2017","journal-title":"Annals of Oncology"},{"key":"2025100312022602000_10.4.e004149.42","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100312022602000_10.4.e004149.43","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxj037"},{"key":"2025100312022602000_10.4.e004149.44","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-196508000-00023"},{"key":"2025100312022602000_10.4.e004149.45","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/his.14433","article-title":"The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation\u2010associated angiosarcomas of the breast","volume":"79","author":"Kuba","year":"2021","journal-title":"Histopathology"},{"key":"2025100312022602000_10.4.e004149.46","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"2025100312022602000_10.4.e004149.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1906-8"},{"key":"2025100312022602000_10.4.e004149.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.03.034"},{"key":"2025100312022602000_10.4.e004149.49","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5936"},{"key":"2025100312022602000_10.4.e004149.50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/cells10040739","article-title":"Crk and CRKL as therapeutic targets for cancer treatment","volume":"10","author":"Park","year":"2021","journal-title":"Cells"},{"key":"2025100312022602000_10.4.e004149.51","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0494-1"},{"key":"2025100312022602000_10.4.e004149.52","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/mc.21935","article-title":"Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer","volume":"52","author":"Wang","year":"2013","journal-title":"Mol Carcinog"},{"key":"2025100312022602000_10.4.e004149.53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56870-5","article-title":"Copy number gains of the putative CRKL oncogene in laryngeal squamous cell carcinoma result in strong nuclear expression of the protein and influence cell proliferation and migration","volume":"10","author":"Kostrzewska-Poczekaj","year":"2020","journal-title":"Sci Rep"},{"key":"2025100312022602000_10.4.e004149.54","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0046"},{"key":"2025100312022602000_10.4.e004149.55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194816","article-title":"Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis","volume":"13","author":"Espejo-Freire","year":"2021","journal-title":"Cancers"},{"key":"2025100312022602000_10.4.e004149.56","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1384"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-004149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:02:55Z","timestamp":1759518175000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,1]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1136\/jitc-2021-004149"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-004149","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}